newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR®